Anterior Uveitis - Pipeline Review, H2 2016

  • ID: 3895079
  • Drug Pipelines
  • 55 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Aciont Inc.
  • KPI Therapeutics, Inc.
  • Neuroptis Biotech
  • MORE
Anterior Uveitis - Pipeline Review, H2 2016

Summary

‘Anterior Uveitis - Pipeline Review, H2 2016’, provides an overview of the Anterior Uveitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anterior Uveitis
- The report reviews pipeline therapeutics for Anterior Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anterior Uveitis therapeutics and enlists all their major and minor projects
- The report assesses Anterior Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anterior Uveitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anterior Uveitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anterior Uveitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Aciont Inc.
  • KPI Therapeutics, Inc.
  • Neuroptis Biotech
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Anterior Uveitis Overview

Therapeutics Development

Pipeline Products for Anterior Uveitis - Overview

Anterior Uveitis - Therapeutics under Development by Companies

Anterior Uveitis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Anterior Uveitis - Products under Development by Companies

Anterior Uveitis - Companies Involved in Therapeutics Development

Aciont Inc.

Aldeyra Therapeutics, Inc.

EyeGate Pharmaceuticals, Inc.

KPI Therapeutics, Inc.

Neuroptis Biotech

Anterior Uveitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

dalazatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone sodium phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LME-636 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NS-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anterior Uveitis - Dormant Projects

Anterior Uveitis - Discontinued Products

Anterior Uveitis - Product Development Milestones

Featured News & Press Releases

May 09, 2016: Aldeyra Therapeutics Announces Positive Results From Phase II Clinical Trial in Subjects With Noninfectious Anterior Uveitis

Mar 02, 2016: EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437

Jan 19, 2016: EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis

May 04, 2015: EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis

Apr 16, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial

Mar 26, 2015: Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial

Mar 19, 2015: Kineta’s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases

Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program

Feb 17, 2015: Kineta to Present New, Positive Data for ShK-186 in Autoimmune Eye Diseases and in ANCA Vasculitis at Upcoming Prestigious Science Conferences

Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis

Apr 09, 2013: EyeGate Pharma's EGP-437 Matches Standard-of-care's Response Rate In Phase III Study In Patients With Anterior Uveitis

Dec 18, 2012: EyeGate Pharma Enrolls Last Patient In Pivotal Phase III Anterior Uveitis Study Of EGP-437

Jan 05, 2012: EyeGate Pharma Initiates Phase III Study Of EGP-437 In Patients With Anterior Uveitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Anterior Uveitis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Anterior Uveitis - Pipeline by Aciont Inc., H2 2016

Anterior Uveitis - Pipeline by Aldeyra Therapeutics, Inc., H2 2016

Anterior Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016

Anterior Uveitis - Pipeline by KPI Therapeutics, Inc., H2 2016

Anterior Uveitis - Pipeline by Neuroptis Biotech, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Anterior Uveitis - Dormant Projects, H2 2016

Anterior Uveitis - Discontinued Products, H2 2016 45List of Figures

Number of Products under Development for Anterior Uveitis, H2 2016

Number of Products under Development by Companies, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Aciont Inc.
  • KPI Therapeutics, Inc.
  • Neuroptis Biotech
  • MORE
Anterior Uveitis pipeline therapeutics constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. Our latest report Anterior Uveitis – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Anterior Uveitis Anterior uveitis is an inflammation of the middle layer of the eye, which includes the iris (colored part of the eye) and ciliary body. Symptoms include a red, sore and inflamed eye, blurring of vision, sensitivity to light and a small pupil. The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 2 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Aciont Inc.
Aldeyra Therapeutics, Inc.
EyeGate Pharmaceuticals, Inc.
KPI Therapeutics, Inc.
Neuroptis Biotech
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll